Interestingly, the RXR agonist Bexarotene was pursued as a treatment for AD (Tousi, 2015), partly due to reported ability to increase APOE expression, but this has been reconsidered (Balducci et al., 2015; Tousi, 2015). This evidence concerns the gene APOE and Alzheimer disease.